Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients

Breast Cancer Research and Treatment

Volumn 131, Issue 2, 2012, Pages 437-444

  Chaher, Nabila ^a   Arias Pulido, Hugo ^b   Terki, Nadija ^a   Qualls, Clifford ^b   Bouzid, Kamel ^a   Verschraegen, Claire ^b   Wallace, Anne Marie ^b   Royce, Melanie ^b  

^a Centre Pierre et Marie Curie   (Algeria)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Disease free survival; Growth factor receptors; Hormone receptors; Inflammatory breast cancer; Locally advanced breast cancer; Overall survival; Tumor emboli; Tumor subtypes

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GOSERELIN; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ALGERIA; ALGERIAN; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHI SQUARE TEST; CONTROLLED STUDY; DEMOGRAPHY; DISEASE FREE SURVIVAL; ETHNIC GROUP; FISHER EXACT TEST; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATORY BREAST CANCER; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PALPATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR EMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ALGERIA; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; RECURRENCE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84856227886     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1422-5     Document Type: Article

References (36)

1. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S et al (2010) International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. doi: 10.1093/annonc/mdq345
2. A Molckovsky B Fitzgerald O Freedman R Heisey M Clemons 2009 Approach to inflammatory breast cancer Can Fam Physician 55 25 31 19155362
3. SE Singletary M Cristofanilli 2008 Defining the clinical diagnosis of inflammatory breast cancer Semin Oncol 35 7 10 18308140 10.1053/j.seminoncol. 2007.11.010 (Pubitemid 351282390)
4. KW Hance WF Anderson SS Devesa HA Young PH Levine 2005 Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute J Natl Cancer Inst 97 966 975 15998949 10.1093/jnci/dji172 (Pubitemid 41430562)
5. H Boussen H Bouzaiene JB Hassouna T Dhiab F Khomsi F Benna A Gamoudi N Mourali M Hechiche K Rahal, et al. 2010 Inflammatory breast cancer in Tunisia Cancer 116 2730 2735 20503401 10.1002/cncr.25175
6. A Soliman M Banerjee A Lo K Ismail A Hablas I Seifeldin M Ramadan H Omar A Fokuda J Harford, et al. 2009 High proportion of inflammatory breast cancer in the Population-based Cancer Registry of Gharbiah, Egypt Breast J 15 432 434 19601951 10.1111/j.1524-4741.2009.00755.x
7. N Mokhtar J Elati R Chabir A Bour K Elkari NP Schlossman B Caballero H Aguenaou 2001 Diet culture and obesity in Northern Africa J Nutr 131 887S 892S 11238780 1:STN:280:DC%2BD3M3hs1antg%3D%3D (Pubitemid 32199164)
8. SI Labidi K Mrad A Mezlini MA Ouarda JD Combes MB Abdallah KB Romdhane P Viens FB Ayed 2008 Inflammatory breast cancer in Tunisia in the era of multimodality therapy Ann Oncol 19 473 480 18006895 10.1093/annonc/mdm480 1:STN:280:DC%2BD1c7ksVajtw%3D%3D (Pubitemid 351325667)
9. S Dey A Soliman S Merajver 2009 Xenoestrogens may be the cause of high and increasing rates of hormone receptor positive breast cancer in the world Med Hypotheses 72 652 656 19155145 10.1016/j.mehy.2008.10.025 1:CAS:528: DC%2BD1MXjvVagu78%3D
10. AC Lo CG Kleer M Banerjee S Omar H Khaled S Eissa A Hablas JA Douglas SH Alford SD Merajver, et al. 2008 Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients Breast Cancer Res Treat 112 141 147 18058225 10.1007/s10549-007-9833-z 1:CAS:528: DC%2BD1cXhtFOjtrnM
11. T Duke N Jahed C Veneroso R Da Roza O Johnson D Hoffman S Barsky P Levine 2010 A cluster of inflammatory breast cancer (IBC) in an office setting: additional evidence of the importance of environmental factors in IBC etiology Oncol Rep 24 1277 1284 20878121
12. PH Levine HA Young L Mark H Rojowsky JF Holland BG Pogo 2009 Increased detection of breast cancer virus sequences in inflammatory breast cancer Adv Tumor Virol 1 3 7
13. B Pogo J Holland P Levine 2010 Human mammary tumor virus in inflammatory breast cancer Cancer 116 2741 2744 20503403 10.1002/cncr.25179
14. E Charafe-Jauffret K Mrad S Intidhar Labidi A Ben Hamida K Ben Romdhane M Ben Abdallah C Ginestier B Esterni D Birnbaum F Ben Ayed, et al. 2007 Inflammatory breast cancers in Tunisia and France show similar immunophenotypes Breast 16 352 358 17360185 10.1016/j.breast.2007.01.002 (Pubitemid 47157807)
15. E Charafe-Jauffret C Tarpin V Bardou F Bertucci C Ginestier A Braud B Puig J Geneix J Hassoun D Birnbaum, et al. 2004 Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature' J Pathol 202 265 273 14991891 10.1002/path.1515 (Pubitemid 38325235)
16. A Ben Hamida IS Labidi K Mrad E Charafe-Jauffret S Ben Arab B Esterni L Xerri P Viens F Bertucci D Birnbaum, et al. 2008 Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin BMC Cancer 8 28 18230143 10.1186/1471-2407-8-28 (Pubitemid 351420103)
17. C Ginestier E Charafe-Jauffret F Bertucci F Eisinger J Geneix D Bechlian N Conte J Adelaide Y Toiron C Nguyen, et al. 2002 Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers Am J Pathol 161 1223 1233 12368196 10.1016/S0002-9440(10)64399-4 1:CAS:528:DC%2BD38Xotlyqu7c%3D
18. G Van den Eynden I Van der Auwera S Van Laere C Colpaert P van Dam S Merajver C Kleer A Harris E Van Marck L Dirix, et al. 2004 Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer Breast Cancer Res Treat 85 13 22 15039594 10.1023/B:BREA.0000021028.33926.a8 (Pubitemid 38437979)
19. N Mourali L Muenz F Tabbane S Belhassen J Bahi P Levine 1980 Epidemiologic features of rapidly progressing breast cancer in Tunisia Cancer 46 2741 2746 7448713 10.1002/1097-0142(19801215)46:12<2741::AID- CNCR2820461234>3.0.CO;2-W 1:STN:280:DyaL3M%2FovVSkug%3D%3D (Pubitemid 11210246)
20. NCI/NHLBI OEITFM Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Bethesda, MD: NHLBI 1998
21. H Arias-Pulido H Smith N Joste T Bocklage C Qualls A Chavez E Prossnitz C Verschraegen 2009 Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors Gynecol Oncol 114 480 485 19560192 10.1016/j.ygyno.2009.05.045 1:CAS:528:DC%2BD1MXptlSrt7g%3D
22. Lachin J (2000) Biostatistical methods. Wiley, New York, pp 272-285
23. MG Lê R Arriagada J Bahi F Pfeiffer M Cammoun F Tabbane C Rubino 2006 Are risk factors for breast cancer similar in women with inflammatory breast cancer and in those with non-inflammatory breast cancer? The Breast 15 355 362 16198566 10.1016/j.breast.2005.08.018 (Pubitemid 43832575)
24. A Lo A Georgopoulos C Kleer M Banerjee S Omar H Khaled S Eissa A Hablas H Omar J Douglas, et al. 2009 Analysis of RhoC expression and lymphovascular emboli in inflammatory vs. non-inflammatory breast cancers in Egyptian patients Breast 18 55 59 19157876 10.1016/j.breast.2008.11.002
25. S Chang J Alderfer L Asmar A Buzdar 2000 Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis Breast Cancer Res Treat 64 157 163 11194451 10.1023/A:1006489100283 1:STN:280: DC%2BD3M7jvFSlsw%3D%3D (Pubitemid 32010333)
26. SA Aziz S Pervez S Khan N Kayani SI Azam MH Rahbar 2001 Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience Breast J 7 398 404 11843851 10.1046/j.1524-4741.2001.07604.x 1:STN:280:DC%2BD387htVCktw%3D%3D (Pubitemid 34024462)
27. S Chang AU Buzdar SD Hursting 1998 Inflammatory breast cancer and body mass index J Clin Oncol 16 3731 3735 9850015 1:STN:280:DyaK1M%2FmsFaltQ%3D%3D (Pubitemid 29001523)
28. FM Robertson M Bondy W Yang H Yamauchi S Wiggins S Kamrudin S Krishnamurthy H Le-Petross L Bidaut AN Player, et al. 2010 Inflammatory breast cancer: the disease, the biology, the treatment CA Cancer J Clin 60 351 375 20959401 10.3322/caac.20082
29. S Dey A Soliman A Hablas I Seifeldein K Ismail M Ramadan H El-Hamzawy M Wilson M Banerjee P Boffetta, et al. 2010 Urban-rural differences in breast cancer incidence in Egypt (1999-2006) Breast 16 417 423 10.1016/j.breast.2010. 04.005
30. G Gruber M Ciriolo H Altermatt S Aebi G Berclaz R Greiner 2004 Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer Int J Cancer 109 144 148 14735481 10.1002/ijc.11684 1:CAS:528:DC%2BD2cXhs1Smuro%3D (Pubitemid 38160675)
31. M Le R Arriagada G Contesso M Cammoun F Pfeiffer F Tabbane J Bahi M Dilaj M Spielmann J Travagli, et al. 2005 Dermal lymphatic emboli in inflammatory and noninflammatory breast cancer: a French-Tunisian joint study in 337 patients Clin Breast Cancer 6 439 445 16381628 10.3816/CBC.2005.n.049 (Pubitemid 43078900)
32. S Dawood N Ueno M Cristofanilli 2008 The medical treatment of inflammatory breast cancer Semin Oncol 35 64 71 18308147 10.1053/j.seminoncol. 2007.11.012 (Pubitemid 351282392)
33. L Gianni W Eiermann V Semiglazov A Manikhas A Lluch S Tjulandin M Zambetti F Vazquez M Byakhow M Lichinitser, et al. 2010 Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Lancet 375 377 384 20113825 10.1016/S0140-6736(09) 61964-4 1:CAS:528:DC%2BC3cXht12ltLk%3D
34. S Johnston M Trudeau B Kaufman H Boussen K Blackwell P LoRusso DP Lombardi S Ben Ahmed DL Citrin ML DeSilvio, et al. 2008 Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy J Clin Oncol 26 1066 1072 18212337 10.1200/JCO.2007.13.9949 1:CAS:528:DC%2BD1cXktVKisbY%3D
35. B Kaufman M Trudeau A Awada K Blackwell T Bachelot V Salazar M DeSilvio R Westlund T Zaks N Spector, et al. 2009 Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study Lancet Oncol 10 581 588 19394894 10.1016/S1470-2045(09)70087-7 1:CAS:528:DC%2BD1MXms12jtbY%3D
36. H Boussen M Cristofanilli T Zaks M DeSilvio V Salazar N Spector 2010 Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer J Clin Oncol 28 3248 3255 20530274 10.1200/JCO.2009.21.8594 1:CAS:528:DC%2BC3cXhtVajur3J